nature > npj digital medicine > articles > article

Article Open Access Published: 19 May 2023

Ontologizing health systems data at scale: making translational discovery a reality

Tiffany J. Callahan ^C, Adrianne L. Stefanski, Jordan M. Wyrwa, Chenjie Zeng, Anna Ostropolets, Juan M. Banda, William A. Baumgartner Jr., Richard D. Boyce, Elena Casiraghi, Ben D. Coleman, Janine H. Collins, Sara J. Deakyne Davies, James A. Feinstein, Asiyah Y. Lin, Blake Martin, Nicolas A. Matentzoglu, Daniella Meeker, Justin Reese, Jessica Sinclair, Sanya B. Taneja, Katy E. Trinkley, Nicole A. Vasilevsky, Andrew E. Williams, Xingmin A. Zhang, Joshua C. Denny, Patrick B. Ryan, George Hripcsak, Tellen D. Bennett, Melissa A. Haendel, Peter N. Robinson, Lawrence E. Hunter & Michael G. Kahn
Show fewer authors

npj Digital Medicine 6, Article number: 89 (2023) Cite this article

2081 Accesses 21 Altmetric Metrics



OHDSI Community Call - September 25, 2023




Background


- Deep phenotyping, or "the precise and comprehensive analysis of phenotypic abnormalities in which the individual components of the phenotype are observed and described"¹, requires timely synthesis of multiple types of patient data²⁻³
- Common data models solve many challenges of standardizing electronic health record (EHR) data but are unable to semantically integrate all of the resources needed for deep phenotyping⁴
- Open Biological and Biomedical Ontology (OBO) Foundry ontologies provide computable representations of biological knowledge and enables the integration of heterogeneous data⁵

Challenge: Mapping EHR data to OBO ontologies requires significant manual curation and domain expertise


Objective: Develop an algorithm that generates <u>clinically meaningful</u> and <u>biologically relevant</u> mappings between standard OMOP vocabularies and Open Biomedical Ontologies





Example Mappings - Condition Occurrences



Example Mappings - Drug Exposure Ingredients







Using OMOP2OBO, we built mappings for 92,367 conditions, 8615 drug ingredients, and 10,673 measurement results to ontology concepts representing 9636 diseases, 6309 phenotypes, 83 anatomical entities, 2704 organisms, 4261 chemicals, 132 vaccines, and 272 proteins

Evaluation

Accuracy

10 domain experts manually reviewed 20% of the most challenging manual OMOP2OBO mappings

- Correct Mappings: 73.9% (condition), 70.7% (drug ingredient), and 92.9% (measurements)

Generalizability

OMOP2OBO mapping concept coverage in 24 Independent hospitals (OHDSI Concept Prevalence Study)

- Coverage: 99.5% of conditions, 99.9% of drug ingredients, and 68% of measurement results

Clinical Utility

Compare OMOP2OBO mappings to validated manual mappings when used to identify patients with rare genetic diseases using AoU data

- Query Performance: OMOP2OBO mappings identified 99.3% of the patients identified by the validated manual mappings using fewer codes and one-third of the query time

Acknowledgements





Tri-Advisory





Dr. Michael G. Kahn

Dr. Lawrence E. Hunter



Dr. Tellen D. Bennett









- Adrianne L. Stefanski, PhD Peter Robinson, MD
- Nicole Vasilevsky, PhD

Melissa Haendel, PhD

Clinical Experts



James Feinstein, MD



Blake Martin, MD

Jordan Wyrwa, DO



Katy Trinkley, PharmD





Patrick Ryan, PhD

Anna Ostropolets, MD

Andrew Williams, PhD





Organizations







Funding: T15LM009451 and T15LM007079





Jessica Sinclair, PharmD

OHDSI / OMOP Experts




Translational Research Experts





Conditions: <u>https://doi.org/10.5281/zenodo.6774363</u> Drug Ingredients: <u>https://doi.org/10.5281/zenodo.6774401</u> Measurements: <u>https://doi.org/10.5281/zenodo.6774443</u>

Dashboard



Evaluation

